



## ESC Declaration of Interest Report

### 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)

The ESC reviews relationships with industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in Guidelines development to comply with the ESC Declaration and Management of Conflict of Interest Policy. Under this policy, they are required to submit yearly Declaration of Interest (DOI) forms during the writing and reviewing phases of the Guidelines.

All DOIs are assessed prior to work commencing, and the ESC may decide to exclude any expert from a Guidelines activity based on the exclusion criteria as defined in the [ESC Declaration and Management of Conflict of Interest Policy](#) and accompanying [2012 ESC Policy statement : Relations between professional medical associations and the health-care industry, concerning scientific communication and continuing medical education](#).

Any form of the following characteristics may disqualify an individual from serving on a Guidelines committee, if related to the guideline topic:

- Part-time employment or salary
- Stock ownership
- Holding of a patent which generates revenues
- Receipt of royalties for intellectual property

The following additional characteristics may also disqualify an individual for the positions of CPG Chairperson, Guidelines Task Force Chairperson and Guidelines Review Coordinator:

- Personally received payments from healthcare industry of 10,000€ or higher per year.
- Payments from healthcare industry of 10,000€ or higher per year, made to one's institution/hospital or to other legal bodies which have generated a direct or indirect personal benefit/asset.

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Arbelo Elena	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Atrial Fibrillation</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Atrial fibrillation</li> </ul>
Bax Jeroen	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Antiplatelets/anticoagulation-lecture</li> <li>- Abbott Vascular : MItraClip - speaker fees</li> </ul> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Antiplatelets/anticoagulation-lecture</li> <li>- Boston Scientific : LAA closure-advisory board review</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : device therapy</li> <li>- Medtronic : device therapy</li> <li>- Biotronik : device therapy</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Bax Jeroen	<p><b>2018</b></p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : transcatheter heart valves</li> <li>- GE Healthcare : ultrasound systems</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- European Associate Editor JNC, Deputy Editor EHJ; (unpaid) steering committees: TAVR UNLOAD (Edwards) -- AURORA (GE Healthcare)</li> </ul>
	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Antiplatelets/anticoagulation - lecture</li> <li>- Edwards Lifesciences : structural heart disease - lecture</li> <li>- Abbott Vascular : Structural heart disease - lecture</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Antiplatelets/anticoagulation-lecture</li> <li>- Boston Scientific : LAA closure-advisory board review</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : device therapy</li> <li>- Medtronic : device therapy</li> <li>- Biotronik : device therapy</li> <li>- Bayer : heart failure</li> <li>- Bioventrix : heart failure</li> <li>- Abott : MitraClip</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Bax Jeroen	<p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : transcatheter heart valves</li> <li>- GE Healthcare : ultrasound systems</li> </ul>
Blomstrom-Lundqvist Carina	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Bayer : anticoagulation</li> <li>- Boehringer-Ingelheim : anticoagulation</li> <li>- Sanofi Aventis : anticoagulation</li> <li>- Merck Sharp &amp; Dohme : anticoagulation</li> <li>- Boston Scientific : devices, atrial fibrillation ablation</li> <li>- Medtronic : devices, atrial fibrillation ablation</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Medtronic : AF</li> <li>- Cardiomeas : drug</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : anticoagulation</li> <li>- Boehringer-Ingelheim : anticoagulation</li> <li>- Sanofi Aventis : anticoagulation</li> <li>- Merck Sharp &amp; Dohme : anticoagulation</li> <li>- Boston Scientific : devices, atrial fibrillation ablation</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Blomstrom-Lundqvist Carina	<p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Medtronic : devices, atrial fibrillation ablation</li> </ul> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For members of your household</p> <ul style="list-style-type: none"> <li>- Biotronik : devices</li> </ul>
Boriani Giuseppe	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Pacemaker, cardioverter defibrillators</li> <li>- Medtronic : Pacemaker, cardioverter defibrillators</li> <li>- Biotronik : Pacemaker, cardioverter defibrillators</li> </ul>
	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Pacemaker, cardioverter defibrillators</li> <li>- Medtronic : Pacemaker, cardioverter defibrillators</li> <li>- Biotronik : Pacemaker, cardioverter defibrillators</li> </ul>
Castella Manuel	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Atricure : Atrial fibrillation ablation</li> <li>- Medtronic : Cardiovascular surgery</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Castella Manuel	<b>2018</b>	Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. - Medtronic : Cardiovascular surgery
	<b>2019</b>	Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Atricure : Atrial fibrillation ablation - Medtronic : Cardiovascular surgery  Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself - Medtronic : Cardiovascular surgery
Dagres Nikolaos	<b>2018</b>	Financial Declaration  Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. - Abbott, Biotronik, Medtronic, Boston Scientific : Electrophysiology, arrhythmias
	<b>2019</b>	Nothing to be declared
Dan Gheorghe Andrei	<b>2018</b>	Financial Declaration  Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Boehringer-Ingelheim : cardiology - Pfizer : Cardiology - Servier : cardiology - Alfa-Wassermann : cardiology

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Dan Gheorghe Andrei	<b>2018</b>	<ul style="list-style-type: none"> <li>- Zentiva : cardiology</li> <li>- Bayer AG : cardiology</li> <li>- Roche Diagnostics : cardiology</li> <li>- Krka Pharma : cardiology</li> </ul>
	<b>2019</b>	<p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : cardiology</li> <li>- Pfizer : Cardiology</li> <li>- Servier : cardiology</li> <li>- Alfa-Wassermann : cardiology</li> <li>- Zentiva : cardiology</li> <li>- Bayer AG : cardiology</li> <li>- Roche Diagnostics : cardiology</li> <li>- Krka Pharma : cardiology</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : ESC</li> </ul>
Dilaveris Polychronis E	<b>2018</b>	<p>Nothing to be declared</p>
	<b>2019</b>	<p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Digital solutions - Advisory board fees</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Dilaveris Polychronis E	<p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Medtronic : Implantable loop recorders - speaker fees</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Pacemakers - ICDs</li> <li>- Biotronik : Pacemakers / ICDs</li> </ul>
Fauchier Laurent	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Bayer : Therapy for cardiovascular diseases</li> <li>- Boehringer-Ingelheim : Therapy for cardiovascular diseases</li> <li>- Medtronic : Therapy for cardiovascular diseases</li> <li>- Novartis : Therapy for cardiovascular diseases</li> <li>- Pfizer : Therapy for cardiovascular diseases</li> <li>- Bristol Myers Squibb : Therapy for cardiovascular diseases</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Healthcare</li> </ul> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For members of your household</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Healthcare</li> <li>- Medtronic : Healthcare</li> <li>- Novartis : Healthcare</li> </ul>



## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Fauchier Laurent	<p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Pfizer : Healthcare</li> <li>- Bristol Myers Squibb : Healthcare</li> </ul>
Filippatos Gerasimos	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure</li> <li>- Servier : Heart Failure</li> </ul> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Bayer : CKD</li> <li>- Vifor International : Heart failure</li> <li>- Boehringer-Ingelheim : Heart failure, Diabetes</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Medtronic : Devices</li> <li>- European Union : Heart Failure</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure</li> <li>- Servier : Heart Failure</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Filippatos Gerasimos	<p><b>2019</b></p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : CKD</li> <li>- Vifor International : Heart failure</li> <li>- Boehringer-Ingelheim : Heart failure, Diabetes</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Devices</li> <li>- European Union : Heart Failure</li> </ul>
Hindricks Gerhard	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Abbott : Pacemaker, Ablation</li> <li>- Biosense Webster : Pacemaker, Ablation</li> <li>- Biotronik : Pacemaker, catheter</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Electrophysiology, arrhythmias</li> <li>- Abbott : Electrophysiology, arrhythmias</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group.</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Hindricks Gerhard	<p><b>2019</b></p> <p>Nothing to be declared</p>
Kalman Jonathan	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Abbott : Unrestricted research grant</li> <li>- Boston Scientific : Unrestricted research grant</li> <li>- Medtronic : Unrestricted research grant</li> <li>- Biosense Webster : Unrestricted research grant</li> </ul> <hr/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Fellows education of EP traces</li> <li>- Biosense Webster : Remodeling of the atrium and mechanisms of persistent AF</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Remodeling of the atrium and mechanisms of persistent AF</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Fellowship support</li> <li>- Biosense Webster : Fellowship support</li> </ul> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. For yourself</p> <ul style="list-style-type: none"> <li>- Associate editor of Journal of The American College of Cardiology-Clinical Electrophysiology</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

La Meir Mark	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Medtronic : ablation</li> <li>- Atricure : ablation</li> </ul> <hr style="border-top: 1px dotted black;"/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Atricure : Arrhythmia</li> </ul>
Lane Deirdre	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Atrial fibrillation</li> <li>- Pfizer : Atrial fibrillation</li> <li>- Bristol Myers Squibb : Atrial fibrillation</li> <li>- Boehringer Ingelheim : Atrial fibrillation</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Pfizer : Atrial fibrillation</li> <li>- Bristol Myers Squibb : Atrial fibrillation</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Lane Deirdre	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Atrial fibrillation</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Atrial fibrillation</li> </ul>
Lebeau Jean-Pierre	<p><b>2018</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2019</b></p> <p>Nothing to be declared</p>
Lettino Maddalena	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulants</li> <li>- Pfizer : Anticoagulants</li> <li>- Bayer Healthcare : Antithrombotic agents, anticoagulants</li> <li>- Sanofi Aventis : Antithrombotic agents, anticoagulants, lipid lowering drugs</li> <li>- Astra Zeneca : Antithrombotic agents, statins</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Lettino Maddalena	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : anticoagulants</li> <li>- Daiichi Sankyo : anticoagulants</li> <li>- Pfizer : anticoagulants</li> <li>- Bristol Myers Squibb : anticoagulants</li> <li>- Amgen : lipid-lowering drugs</li> <li>- Sanofi Aventis : lipid-lowering drugs</li> </ul>
Lip Gregory Yh	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Daiichi-Sankyo : Anticoagulation</li> <li>- Bayer/Janssen : Anticoagulation</li> <li>- Verseon : Anticoagulation development</li> <li>- Boehringer Ingelheim : Anticoagulation; Registries; Steering Committees</li> <li>- Pfizer : Anticoagulation; Registries</li> <li>- BMS : Antithrombotic therapy</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : AF registries [unrestricted educational grant]</li> <li>- BMS/Pfizer : AF registries [unrestricted educational grant]</li> <li>- Daiichi-Sankyo : Systematic reviews [unrestricted educational grant]</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Lip Gregory Yh	<p><b>2018</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- Shares in private limited company (a legal separate entity in UK), but no salary/dividends/income/personal remuneration received.</li> </ul>
	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi-Sankyo : Anticoagulation</li> <li>- Bayer/Janssen : Anticoagulation</li> <li>- Verseen : Anticoagulation development</li> <li>- Boehringer Ingelheim : Anticoagulation; Registries; Steering Committees</li> <li>- Pfizer : Anticoagulation; Registries</li> <li>- BMS : Antithrombotic therapy</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : AF registries [unrestricted educational grant]</li> <li>- BMS/Pfizer : AF registries [unrestricted educational grant]</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> <li>- Shares in private limited company (a legal separate entity in UK), but no salary/dividends/income/personal remuneration received.</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Pinto Fausto Jose	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Pfizer : Apixaban</li> <li>- Menarini : Coronary artery disease and hypertension</li> <li>- Boehringer-Ingelheim : Dabigatran</li> <li>- Daichi Sankyo : Edoxaban</li> <li>- Biotronik : Interventional cardiology</li> <li>- Servier : Ivabradine, Perindopril, Trimetazidine</li> <li>- Vifor International : Patiromer</li> <li>- Bayer Healthcare : Rivaroxaban</li> <li>- Novartis : Serelaxin, Entresto</li> </ul> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Medtronic : CRT</li> <li>- Biotronik : Interventional cardiology and EP</li> <li>- Abbott Vascular : Interventional Cardiology and EP</li> <li>- Servier : Ivabradine</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anti thrombotics</li> <li>- Medtronic : CRT</li> </ul>
-------------------	--



## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Pinto Fausto Jose	<b>2018</b>	<ul style="list-style-type: none"> <li>- Novartis : Heart Failure</li> <li>- Servier : Ivabradine</li> <li>- St Jude Medical : PCI, EP</li> <li>- GE Healthcare : Ultrasound equipment</li> </ul>
	<b>2019</b>	<p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Apixaban</li> <li>- Menarini : Coronary artery disease and hypertension</li> <li>- Boehringer-Ingelheim : Dabigatran</li> <li>- Daichi Sankyo : Edoxaban</li> <li>- Biotronik : Interventional cardiology</li> <li>- Servier : Ivabradine, Perindopril, Trimetazidine</li> <li>- Vifor International : Patiromer</li> <li>- Bayer Healthcare : Rivaroxaban</li> <li>- Novartis : Serelaxin, Entresto</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Medtronic : CRT</li> <li>- Biotronik : Interventional cardiology and EP</li> <li>- Abbott Vascular : Interventional Cardiology and EP</li> <li>- Servier : Ivabradine</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Pinto Fausto Jose	<p><b>2019</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anti thrombotics</li> <li>- Medtronic : CRT</li> <li>- Novartis : Heart Failure</li> <li>- Servier : Ivabradine</li> <li>- St Jude Medical : PCI, EP</li> <li>- GE Healthcare : Ultrasound equipment</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- President Elect of World Heart Federation (WHF)</li> </ul>
Potpara Tatjana	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Bayer : oral anticoagulants</li> </ul> <hr/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : atrial fibrillation</li> </ul>
Thomas G Neil	<p><b>2018</b></p> <p>Nothing to be declared</p>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Thomas G Neil	<b>2019</b>  Nothing to be declared
Valgimigli Marco	<b>2018</b>  Financial Declaration  Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. <ul style="list-style-type: none"> <li>- Amgen : Advisory Board</li> <li>- Astra Zeneca : Antiplatelet agents</li> <li>- Daiichi Sankyo : Consultancy -TAVI studies</li> <li>- Terumo Inc : Coronary stent</li> <li>- Abbott Vascular : Coronary Stent</li> <li>- Opsens : coronary stent</li> <li>- Alvimedica : FFR technology</li> <li>- Coreflow : Intracoronary catheter for the assessment and treatment of microvascular obstruction in patients with acute myocardial infarction.</li> <li>- Bayer : Oral anticoagulation</li> <li>- Idorsia : Parenteral P2Y12 inhibitor</li> </ul> Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. <ul style="list-style-type: none"> <li>- Astra Zeneca : Anti platelet agents</li> <li>- Medicure : Antiplatelet agents</li> <li>- Terumo Inc : Coronary stent</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Valgimigli Marco	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet agents</li> <li>- Daiichi Sankyo : Consultancy -TAVI studies</li> <li>- Terumo Inc : Coronary stent</li> <li>- Abbott Vascular : Coronary Stent</li> <li>- Alvimedica : coronary stent</li> <li>- Bayer : Oral anticoagulation</li> <li>- Idorsia : Parenteral P2Y12 inhibitor</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Antiplatelet agents</li> <li>- Terumo Inc : Coronary stent</li> </ul>
Van Gelder Isabelle C	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Medtronic : ILR</li> <li>- Bayer : NOAC</li> <li>- Daiichi Sankyo : NOAC</li> <li>- BMS : NOAC</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Van Gelder Isabelle C	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- BMS : Atrial fibrillation</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- BMS : Atrial fibrillation</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Atrial fibrillation</li> <li>- Medtronic : Atrial fibrillation</li> </ul>
Van Putte Bart	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Atricure Europe B.V. : surgical ablation</li> </ul> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Atricure Europe B.V. : surgical ablation</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Atricure : surgical ablation</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Van Putte Bart	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Atricure Europe B.V. : surgical ablation</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Atricure Europe B.V. : surgical ablation</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Atricure : surgical ablation</p>
Watkins Dame Caroline Leigh	<p><b>2018</b></p> <p>Nothing to be declared</p>
	<p><b>2019</b></p> <p>Nothing to be declared</p>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Abdel Aziz Ahmed	<b>2019</b>  Nothing to be declared
Abid Leila	<b>2019</b>  Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself <ul style="list-style-type: none"> <li>- Novo-Nordisk : diabetes</li> <li>- Abbott : hypertension</li> <li>- Boehringer-Ingelheim : hypertension</li> <li>- Novartis : hypertension</li> <li>- Servier : hypertension</li> <li>- Sanofi Aventis : hypertension</li> <li>- Menarini : hypertension</li> </ul> Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself <ul style="list-style-type: none"> <li>- Sanofi Aventis : aprovasc</li> <li>- Novartis : exforge</li> <li>- Abbott : odrik</li> </ul>
Aboyans Victor	<b>2019</b>  Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself <ul style="list-style-type: none"> <li>- Bayer : Antithrombotic therapy</li> <li>- BMS/Pfizer Alliance : Antithrombotic therapy</li> <li>- NovoNordisk : Diabetes</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Aboyans Victor	<b>2019</b> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure</li> <li>- Amgen : Lipid lowering therapy</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapy</li> </ul>
Ahlsson Anders	<b>2019</b> <p>Nothing to be declared</p>
Anfinsen Ole-Gunnar	<b>2019</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AS Norway : Electrocardiography in arrhythmias (speaker fee)</li> </ul>
Arnar David O	<b>2019</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- DeCODE genetics : Genetics</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Cardiology</li> </ul>
Arribas Fernando	<b>2019</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Advisory Board</li> <li>- Boston Scientific : Advisory Board</li> <li>- Bristol Myers Squibb : Advisory Board</li> </ul>



## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Arribas Fernando	<p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Arrhythmia Network Technology SL / BAROSTIM : Advisory Board / Speaker fee</li> <li>- Abbott : Advisory Board, Education</li> <li>- Impulse Dynamics : Speaker fee,</li> <li>- Medtronic : Speaker fee, Education</li> <li>- Daiichi Sankyo : Speaker,</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Education in Structural Interventionism</li> <li>- Daiichi Sankyo : Education on Handheld Echo-Doppler for non-cardiologists</li> <li>- Boston Scientific : Left Bundle Branch Block and Resynchchronization</li> <li>- Novartis : Preceptorship in Heart Failure</li> <li>- Bayer : Prevalence and classification of valve heart disease in the population</li> <li>- Janssen-Cilag : Pulmonary Arterial Hypertension</li> <li>- Biosensors : Stenting in Chronic Coronary Artery Disease</li> <li>- Medtronic : Sudden Cardiac Death and Channelopathies</li> </ul>
Atar Ilyas	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : ADVISORY BOARD FEES</li> <li>- Bayer : SPEAKER FEES</li> <li>- Daiichi Sankyo : SPEAKER FEES</li> </ul>
Avraamides Panayiotis	<p><b>2019</b></p> <p>Nothing to be declared</p>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Balsam Pawel	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : heart failure</li> <li>- Novartis : Heart failure</li> <li>- Bayer : NOAC</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself</p> <ul style="list-style-type: none"> <li>- Media - HeartTeam LLC Education - HeartTeam LLC Supplier - HeartTeam LLC</li> </ul>
Barsheshet Alon	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Apixaban</li> <li>- Boehringer-Ingelheim : Pradaxa</li> </ul>
Bates Matthew	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : AF</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Biotronik : EHRA grant</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Bauersachs Johann	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Abiomed : acute heart failure</li> <li>- Daiichi Sankyo : Afib</li> <li>- Pfizer : Afib, Amyloidosis</li> <li>- Boehringer-Ingelheim : Afib, Diabetes mellitus, Heart Failure</li> <li>- Bayer : Afib, heart failure</li> <li>- Bristol Myers Squibb : Afib, heart failure</li> <li>- Merck Sharp &amp; Dohme : CAD, Hypercholesterolemia, heart failure</li> <li>- Abbott : Heart Failure</li> <li>- Medtronic : Heart Failure</li> <li>- Novartis : Heart Failure</li> <li>- Servier : Heart Failure</li> <li>- CVRx : Heart Failure</li> <li>- Vifor International : heart failure, hyperkalemia</li> <li>- Astrazeneca : heart failure, hyperkalemia</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Zoll Medical : Arrhythmia</li> <li>- Abiomed : cardiogenic shock</li> <li>- Vifor International : Heart failure</li> <li>- CVRx : Heart Failure</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Benussi Stefano	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Atricure : Ablation Surgery</li> <li>- Cryolife : FA Ablation Surgery</li> <li>- Allergan : PI on a study on perioperative AF prevention</li> </ul>
Bertelli Luca	<p><b>2019</b></p> <p>Nothing to be declared</p>
Boskovic Aneta	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Acute Coronary Syndrome</li> <li>- Servier : Arterial hypertension</li> <li>- Sanofi Aventis : PTE</li> </ul>
Boveda Serge	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Arrhythmias (ablation)</li> <li>- Microport : Arrhythmias (ICD)</li> <li>- Boston Scientific : Arrhythmias (S-ICD)</li> <li>- Zoll Medical : WCD</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Brandes Axel	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Oral anticoagulants</li> <li>- Bristol Myers Squibb : Oral anticoagulants</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Biotronik : EHRA 2019 Congress</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Danish Heart Foundation Arrhythmia Alliance, UK</li> </ul>
Braunschweig Frieder	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulation</li> <li>- Pfizer : Anticoagulation</li> <li>- Novartis : Heart Failure</li> <li>- Orion : Heart Failure</li> <li>- Abbott : Pacemaker</li> <li>- Medtronic : Pacemaker</li> <li>- Biotronik : Pacemaker</li> </ul>
Bytyci Ibadete	<p><b>2019</b></p> <p>Nothing to be declared</p>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Caldarola Pasquale	<b>2019</b>  Nothing to be declared
Camm John	<b>2019</b>  Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself <ul style="list-style-type: none"> <li>- Pfizer : Anticoagulation for atrial fibrillation</li> <li>- Bristol Myers Squibb : Apixaban</li> <li>- Johnson and Johnson : Cardiovascular safety of non-cardiac drug</li> <li>- Wiley Blackwell : Clinical Cardiology</li> <li>- Biotronik : DSMB - Ablation</li> <li>- Allergan : DSMB for BotulinumToxin use in atrial fibrillation</li> <li>- Oxford University Press : Editor in Chief of European Heart Journal - Case Reports</li> <li>- Daiichi Sankyo : Edoxaba anticoagulation for atrial fibrillation</li> <li>- Oxford University Press : European Heart Journal Case Reports and ESC textbook</li> <li>- Abbott : Events Committee and Organisation of Annual Sympoium</li> <li>- Boston Scientific : General advice and left atrial appendag occlusion device</li> <li>- InCarda : Inhaled flecainide</li> <li>- OMEICOS : New Antiarrhythmic drug for atrial fibrillation</li> <li>- Acesion : New Antiarrhythmic drug for atrial fibrillation</li> <li>- Milestone : New calcium channel blocker</li> <li>- Menarini : Ranolazine</li> <li>- Bayer : Rivaroxaban</li> <li>- Medtronic : Subcutaneous monitoring</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Camm John	<p><b>2019</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Thrombosis Research Institute : Anticoagulation for atrial fibrillation</li> <li>- ARCAN : Oncology products</li> <li>- Cardiac Insight : Solo</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself</p> <ul style="list-style-type: none"> <li>- Education - Several webinars for the ACC</li> </ul> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- President of Arrhythmia Alliance - registered charity - no payment</li> <li>- Trustee of Atrial Fibrillation Society - registered charity - no payment</li> </ul>
Capodanno Davide	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antithrombotic therapy</li> <li>- Bayer : Antithrombotic therapy</li> <li>- Boehringer-Ingelheim : Antithrombotic therapy</li> <li>- Daiichi Sankyo : Antithrombotic therapy</li> <li>- Sanofi Aventis : Antithrombotic therapy</li> <li>- Abbott : PCI</li> <li>- Biosensors : PCI</li> <li>- Boston Scientific : PCI</li> <li>- Amgen : Pharmacology</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Capodanno Davide	<p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself</p> <ul style="list-style-type: none"> <li>- Supplier - Minor shareholder of CERC, an European CRO provider</li> </ul>
Casadei Barbara	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- iRhythm : AF screening</li> <li>- Roche Diagnostics : blood biomarkers of acute kidney injury and incident AFib in the STICS trial</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. For yourself</p> <ul style="list-style-type: none"> <li>- <a href="https://moretrials.net/">https://moretrials.net/</a> British Heart Foundation</li> </ul>
Cavaco Diogo Magalhaes	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Micra pacemaker</li> <li>- Boston Scientific : SCD</li> </ul>
Chasnoits Alexandr	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : antithrombotic therapy</li> </ul>



## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Conen David	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Servier : Oral Anticoagulation</li> </ul>
Crijns Harry	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Atrial fibrillation</li> <li>- Abbott : Education</li> <li>- Medtronic : Education</li> </ul>
Csanadi Zoltan	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : antiplatelet therapy</li> <li>- Egis Pharma : cardiology</li> <li>- Medtronic : Electrophysiology</li> <li>- Sanofi Aventis : hyperlipidemia</li> <li>- Boehringer-Ingelheim : NOAC</li> <li>- Pfizer : NOAC</li> <li>- Merck Sharp &amp; Dohme : NOAC</li> <li>- Bayer AG : NOAC</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
de Groot Natasja	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : electrophysiology</li> </ul>
De Pauw Michel	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary Hypertension</li> </ul>
Delassi Tahar	<p><b>2019</b></p> <p>Nothing to be declared</p>
Delgado Victoria	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- GE Healthcare : 3-dimensional imaging workshop (2000 euro)</li> <li>- Medtronic : aortic stenosis (payment speaker fee 900 euro)</li> <li>- Bayer : diabetes - steering committee (750 euro)</li> <li>- Abbott Vascular : Mitraclip (payment speaker fee 1200 euro)</li> <li>- Edwards Lifesciences : tricuspid valve (payment speaker fee 1200 euro)</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Delgado Victoria	<p><b>2019</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Aortic valve stenosis</li> <li>- Bayer : Heart failure</li> <li>- Bioventrix : heart failure</li> <li>- Abbott Vascular : Mitraclip</li> <li>- Edwards Lifesciences : Tricuspid valve</li> </ul>
Dobrev Dobromir	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Omeicos Therapeutics GmbH, Robert-Rössle-Str.10, 13125 Berlin : Developing groundbreaking therapies in atrial fibrillation and ophthalmology</li> <li>- Acesion Pharma Aps, Ole Maaloesevej 3, DK-2200 Copenhagen : Developing more efficacious and safe drugs for the treatment of atrial fibrillation</li> <li>- Sanofi Aventis : Drug Development</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Omeicos Therapeutics GmbH, Robert-Rössle-Str.10, 13125 Berlin : Fibrotic and inflammatory indices in atrial fibrillation</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- I am Editor-in-Chief of Int J Cardiol Heart Vasc and Deputy-Editor of Int J Cardiol. For my services for both journals I get compensation from Elsevier.</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Drexel Heinz	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Medical University Graz: lecture honoraria : Atherosclerosis</li> <li>- Sanofi: lecture honoraria : Cardiology</li> <li>- MAW: lecture honoraria : Cardiology</li> <li>- Servier: lecture honoraria : Cardiology</li> <li>- ESC: Webinar : Cardiology</li> <li>- Boehringer Ingelheim: consulting activity : Diabetes</li> <li>- Amgen: lecture honoraria : Lipids</li> <li>- MSD: lecture honoraria : Lipids</li> <li>- Medizin Media Austria: consulting activity : Lipids</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Lipids</li> <li>- Sanofi Aventis : Lipids</li> </ul>
Eckardt Lars	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER</li> <li>- Boehringer-Ingelheim : SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER</li> <li>- Boston Scientific : SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Eckardt Lars	<p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER</li> <li>- Medtronic : SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER</li> <li>- Biotronik : SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER</li> <li>- Bayer Healthcare : SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER</li> <li>- Bristol Myers Squibb : SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Deutsche Forschungsgemeinschaft : Research Funding</li> <li>- German Cardiac Society : Research Funding</li> </ul>
Fitzsimons Donna	<p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Member of Scientific Advisory Board of Northern Ireland Chest Heart &amp; Stroke (Non-Paid)</li> </ul>
Folliguet Thierry	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Llvanova : RCT study</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : travel fees</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Fras Zlatko	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : anticoagulation therapy</li> <li>- Pfizer : anticoagulation therapy</li> <li>- Astra Zeneca : antiplatelet therapy</li> <li>- Novo-Nordisk : cardiometabolism</li> <li>- Krka Pharma : hypertension, lipids</li> <li>- Amgen : lipid treatment</li> <li>- Sanofi Aventis : lipid treatment</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- ESC Advocacy Committee</li> </ul>
Gale Christopher Peter	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : ACS</li> <li>- Daiichi Sankyo : AF</li> <li>- Novartis : coronary artery disease</li> <li>- Bayer : coronary artery disease, AF</li> <li>- Vifor International : heart failure</li> <li>- Menarini : ischaemic heart disease</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Gale Christopher Peter	<p><b>2019</b></p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- BMS : AF</li> <li>- Abbott : Diabetes</li> <li>- National Institute for Health Research : MI</li> <li>- British Heart Foundation : MI, AF</li> <li>- Horizon 2020 : post MI sudden cardiac death</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : AF</li> <li>- Bayer Healthcare : AF, CAD</li> <li>- National Institute for Health and Clinical Excellence : Indicator Advisory Committee</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Apixiban, AF</li> </ul>
Galvin Joseph	<p><b>2019</b></p> <p>Nothing to be declared</p>
Gerdes Christian	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Carto System</li> <li>- Abbott : EP System</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Gorenec Bulent	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Sandoz : BETA BLOCKER THERAPY</li> <li>- Astra Zeneca : BETA BLOCKER THERAPY, HYPERTENSION</li> </ul>
Groben Laurent	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Rhythmology congress</li> <li>- Biosense Webster : Rhythmology training</li> </ul>
GROSU Aurel	<p><b>2019</b></p> <p>Nothing to be declared</p>
Haeusler Karl Georg	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : AF</li> <li>- Boehringer-Ingelheim : AF</li> <li>- Daiichi Sankyo : AF</li> <li>- Pfizer : AF</li> <li>- Biotronik : AF</li> <li>- Edwards Lifesciences : TAVI</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Vital : AF</li> </ul>



## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Hatala Robert	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Servier : antihypertensive therapy</li> <li>- Pfizer : antithrombotic therapy</li> <li>- Merck Sharp &amp; Dohme : antithrombotic therapy</li> <li>- Bayer AG : antithrombotic therapy</li> <li>- Boehringer-Ingelheim : antithrombotic therapy, diabetes</li> <li>- Medtronic : atrial fibrillation</li> <li>- IRIS : clinical trials management</li> <li>- Novartis : heart failure</li> <li>- Amgen : myocardial infarction</li> </ul> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For members of your household</p> <ul style="list-style-type: none"> <li>- Servier : Antihypertensive therapy</li> <li>- Pfizer : antithrombotic therapy</li> <li>- Merck Sharp &amp; Dohme : antithrombotic therapy</li> <li>- Amgen : hypolipidemic therapy</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : CRM</li> <li>- Medtronic : CRM</li> <li>- Sorin Group : CRM</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Hatala Robert	<p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Biotronik : CRM</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : anithrombotic therapy</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For members of your household</p> <ul style="list-style-type: none"> <li>- Pfizer : valvular heart disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : CRM</li> </ul>
Heidbuchel Hein	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : AF ablation symposium</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Biotronik : CIED</li> <li>- Abbott : CIED &amp; structural heart</li> <li>- Boston Scientific : CIED &amp; structural heart</li> <li>- Medtronic : CIED &amp; structural heart</li> <li>- Daiichi Sankyo : CV drugs</li> <li>- Pfizer/BMS : CV drugs</li> </ul>
Iung Bernard	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Cardiovascular devices</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Juhlin Tord	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Speaker fees, Atrial fibrillation</li> <li>- Boehringer-Ingelheim : Speaker fees, Atrial fibrillation</li> <li>- MSD : Speaker fees, Atrial fibrillation</li> </ul>
Kalejs Oskars	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Servier : Cardiovascular Pharmacotherapy</li> <li>- Boehringer-Ingelheim : Cardiovascular Pharmacotherapy.</li> <li>- Novartis : Cardiovascular Pharmacotherapy.</li> <li>- Bayer AG : Cardiovascular Pharmacotherapy.</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Treatment of Atrial Fibrillation, Catheter Ablation</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Latvian Research Institute of Cardiology : Treatment of Heart Failure and Arrhythmias</li> </ul>
Kampus Priit	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : speaker fee</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Kampus Priit	<b>2019</b> Travel and meeting support from healthcare industry, independent of the above activities. For yourself - Abbott : travel support
Katus Hugo	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Daiichi Sankyo : Anticoagulants - Bayer Vital : Anticoagulants - Astrazeneca : Antiplatelet - Novartis : Heart Failure Therapies - Boston Scientific : PCI  Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself - Daiichi Sankyo : Anticoagulations - Roche Diagnostics : Biomarker
Kautzner Josef	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Medtronic : catheters, devices - Biotronik : catheters, devices - St Jude Medical : catheters, devices, mapping systems - Biosense Webster : catheters, mapping systems - Bayer : drugs - Boehringer-Ingelheim : drugs

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Kautzner Josef	<b>2019</b> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : drugs</li> <li>- Pfizer : drugs</li> <li>- Promed : drugs</li> <li>- MSD : drugs</li> <li>- Mylan : drugs</li> </ul>
Kerimkulova Alina	<b>2019</b> <p>Nothing to be declared</p>
Kirchhof Paulus	<b>2019</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Institut für Gesundheitsforschung Vallendar e.V. : higher education</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : cardiovascular</li> <li>- Pfizer : cardiovascular</li> <li>- Roche Diagnostics : cardiovascular</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : cardiovascular</li> <li>- Daiichi Sankyo : cardiovascular</li> <li>- Sanofi Aventis : cardiovascular</li> <li>- British Heart Foundation : cardiovascular</li> <li>- BMS / Pfizer alliance : cardiovascular</li> <li>- Leducq Foundation : cardiovascular</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<p><b>2019</b></p> <ul style="list-style-type: none"> <li>- European Union horizon2020 : cardiovascular</li> <li>- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular</li> <li>- UK Medical Research Council : cardiovascular</li> <li>- NIHR (UK National Institute of Health Research) : cardiovascular</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself</p> <ul style="list-style-type: none"> <li>- Education - AFNET (chair of board)</li> </ul> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- membership in several national cardiology societies and subspecialty societies.</li> </ul>
Kojic Dejan	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Advisory board member</li> <li>- Medtronic : Investigator: CB Registry</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Investigator: CB Registry</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : EHRA congress 2019</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- MyoKardia : Clinical trials in heart failure and atrial fibrillation (Advisory Board)</li> <li>- Bayer : Data Science (Advisory Board)</li> <li>- Amomed : Product development in heart failure and atrial fibrillation (Advisory Board)</li> <li>- Atricure : Symposium on atrial fibrillation (Speaker fees)</li> </ul>
Kuhne Michael	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Daiichi Sankyo : Anticoagulation</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Electrophysiology</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Oral anticoagulation</li> <li>- Daiichi Sankyo : Oral anticoagulation</li> <li>- Pfizer-BMS : Oral anticoagulation</li> </ul>
Landmesser Ulf	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Advisory Board fees</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Medicines Company : Advisory Board fees</li> <li>- Bayer : Speaker fee</li> <li>- Amgen : Speaker fees</li> <li>- Sanofi Aventis : Speaker fees</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Research Grant</li> </ul>
Leclercq Christophe	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : devices</li> <li>- Boston Scientific : devices</li> <li>- Medtronic : devices</li> <li>- Biotronik : devices</li> <li>- Microport : devices</li> <li>- Zoll Medical : WCD</li> </ul>
Lewis Basil S	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novo-Nordisk : Diabetes</li> <li>- Merck Sharp &amp; Dohme : Heart failure</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul>



## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Lewis Basil S	<p><b>2019</b></p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Diabetes</li> <li>- Merck Sharp &amp; Dohme : Heart failure</li> <li>- Kowa : Lipidology</li> <li>- Resverlogix : Lipidology. secondary prevention</li> </ul>
Mascherbauer Julia	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Amyloidosis</li> <li>- Abbott : MitraClip</li> <li>- Boston Scientific : TAVR</li> <li>- Edwards Lifesciences : TAVR</li> </ul>
Merino Jose Luis	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : atrial fibrillation and anticoagulation</li> <li>- Sanofi Aventis : Atrial fibrillation and dronedarone</li> <li>- Correio : Atrial fibrillation and Vernakalant</li> <li>- Boston Scientific : Catheter ablación, desfibrillators</li> <li>- Abbott : Catheter ablation</li> <li>- Biosense : Catheter ablation</li> <li>- Microport : Catheter ablation, desfibrillators</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Merino Jose Luis	<p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Biotronik : Defibrillators and pacemakers</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Correio : Atrial fibrillation</li> <li>- Bayer : Atrial fibrillation and Anticoagulation</li> <li>- Boehringer-Ingelheim : Atrial fibrillation and Anticoagulation</li> <li>- Daiichi Sankyo : Atrial fibrillation and Anticoagulation</li> <li>- Pfizer : Atrial fibrillation and Anticoagulation</li> <li>- Bristol Myers Squibb : Atrial fibrillation and Anticoagulation</li> <li>- Elsevier : Bibliography software</li> <li>- Biosense : Catheter ablation</li> <li>- Abbott : Catheter ablation and Defibrillators</li> <li>- Boston Scientific : Catheter ablation and Defibrillators</li> <li>- Medtronic : Catheter ablation and Defibrillators</li> <li>- Microport : Catheter ablation and Defibrillators</li> <li>- Biotronik : Defibrillators</li> <li>- Nuubo : ECG monitoring</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : ESC congress</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Atrial fibrillation ablation and Defibrillators</li> <li>- Daiichi Sankyo : Atrial fibrillation and Anticoagulation</li> <li>- Biotronik : Cardiac Resynchronization</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Merino Jose Luis	<p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Spanish Society of Cardiology</li> </ul>
Merkely Bela	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : CRT course</li> <li>- Abbott : CRT/ICD</li> <li>- Astra Zeneca : HF</li> <li>- Biotronik : ICD/CRT</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : cardiac rhythm management</li> <li>- Boston Scientific : CRT</li> </ul>
Mikhaylov Evgeny	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Atrial fibrillation, anticoagulation</li> <li>- Biosense Webster : Atrial fibrillation, Ventricular tachycardia</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Atrial fibrillation ablation</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Mikhaylov Evgeny	<p><b>2019</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulation</li> <li>- Biosense Webster : Ventricular tachycardia, atrial fibrillation ablation</li> </ul>
Mitkowski Przemyslaw Piotr	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : CIED</li> <li>- Medtronic : CIED</li> <li>- Biotronik : CIED</li> <li>- Abbott Vascular : CIED</li> <li>- Servier : Drugs HF, Hypertension</li> <li>- Hammermed : Lead extraction</li> <li>- Bayer : NOAC</li> <li>- Boehringer-Ingelheim : NOAC</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Biotronik : CIED</li> <li>- Abbott Vascular : CIED</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : NOAC</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : CIED</li> <li>- Abbott Vascular : CIED</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Mitkowski Przemyslaw Piotr	<p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Opera : CIED in Hypertension</li> </ul> <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : CIED</li> <li>- Abbott Vascular : CIED</li> <li>- Opera : CIED in hypertension</li> </ul>
Mont Lluís	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : EP</li> <li>- Boston Scientific : EP-Pacing</li> <li>- Medtronic : EP-Pacing</li> <li>- Abbott Medical : EP-Pacing</li> <li>- Biotronik : Pacing</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : EP</li> <li>- Boston Scientific : EP-Pacing</li> <li>- Medtronic : EP-Pacing</li> <li>- Abbot Medical : EP-Pacing</li> <li>- Biotronik : Pacing</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Shareholder of Galgo Medical S.L.</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Moustaghfir Abdelhamid	<b>2019</b>  Nothing to be declared
Mueller Christian Eugen	<b>2019</b>  Financial Declaration  Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself <ul style="list-style-type: none"> <li>- Bayer : Anticoagulants</li> <li>- Daiichi Sankyo : Anticoagulants</li> <li>- Boehringer-Ingelheim : Antidiabetics</li> <li>- Astra Zeneca : Anti-Diabetics</li> <li>- Idorsia : Antiplatelet therapy</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Acon : Diagnostics</li> <li>- Novartis : Heart Failure</li> <li>- Sanofi Aventis : Lipid lowering</li> <li>- Amgen : Lipid-lowering</li> </ul> Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself <ul style="list-style-type: none"> <li>- Novartis : Diagnostics</li> <li>- OrthoClinical Diagnostics : Diagnostics</li> <li>- Abbott Laboratories : Diagnostics</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Siemens : Diagnostics</li> <li>- Sphingotec : Diagnostics</li> <li>- quidel : Diagnostics</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Nagy Klaudia Vivien	<b>2019</b>  Nothing to be declared
Njeim Mario	<b>2019</b>  Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulation</li> <li>- Boston Scientific : S-ICD</li> </ul> Travel and meeting support from healthcare industry, independent of the above activities. For yourself <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : EHRA meeting</li> <li>- Medtronic : HRS meeting</li> </ul>
Oldgren Jonas	<b>2019</b>  Financial Declaration  Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself <ul style="list-style-type: none"> <li>- Bayer : Cardiology</li> <li>- Boehringer-Ingelheim : Cardiology</li> <li>- Sanofi Aventis : Cardiology</li> <li>- Portola Pharmaceuticals : Cardiology</li> <li>- Bristol Myers Squibb : Cardiology</li> <li>- Roche Diagnostics : Cardiology</li> <li>- Daiichi Sankyo : Cardiology</li> <li>- Astra Zeneca : Cardiology, Diabetes</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Oldgren Jonas	<b>2019</b> Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Roche Diagnostics : Cardiology
Papiashvili Giorgi	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Medtronic : Investigator, Phased RF - Servier : Speaker fee - Astra Zeneca : speaker fee; beta-blockers - Bayer : speaker fee; stroke prevention in atrial fibrillation - Pfizer : speaker fee; stroke prevention in atrial fibrillation  Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Abbott : travel for training organized by Abbott - Bayer : travel to the ESC congress 2019
Pavlovic Nikola	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Biosense Webster : Ablation - Medtronic : Ablation and devices - Bayer : Afib/NOACs - Boehringer-Ingelheim : Afib/Noacs - Pfizer : Afib/NOACs



## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Pavlovic Nikola	<p><b>2019</b></p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Afib ablation</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Ablation</li> <li>- Medtronic : AF ablation</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Cryoballoon ablation</li> <li>- European Research Foundation FP7 : EUCERT</li> </ul>
Pedretti Roberto Franco Enrico	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : DOACs</li> <li>- Boston Scientific : ICDs</li> </ul>
Petersen Steffen Erhard	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself</p> <ul style="list-style-type: none"> <li>- Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<b>2019</b> Membership or affiliation in political or advocacy groups working in the field of cardiology.For yourself - Member of the advocacy committee for the Society of Cardiovascular Magnetic Resonance (SCMR).
Piccini Jonathan	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Sanofi Aventis : Atrial fibrillation - Allergan : Atrial fibrillation - MyoKardia : Atrial fibrillation - ARCA biopharma : Atrial fibrillation - Abbott : Catheter Ablation - Llvanova : Clinical event adjudication - Philips : Lead extraction & Imaging - Medtronic : Leadless Pacing & Atrial Fibrillation - Boston Scientific : Left atrial appendage closure - Biotronik : Outcomes Research - Milestone : Supraventricular tachycardia  Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Abbott : Atrial fibrillation - Bayer : Atrial fibrillation; Anticoagulation - American Heart Association : Get With The Guidelines - Boston Scientific : ICD event adjudication - Philips : Lead extraction - Association for the Advancement of Medical Instrumentation : Lead stress

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Popescu Bogdan Alexandru	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- GE Healthcare : Imaging</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Drug company - antithrombotic drugs</li> </ul>
Poposka Lidija	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Alkaloid Skopje : CVD prevention</li> <li>- Bayer : NOAC</li> <li>- Pfizer : NOAC</li> </ul>
Puererfellner Helmut	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Catheter Ablation</li> <li>- Abbott : Catheter Ablation , PM and ICDs, Loop recorders</li> <li>- Boston Scientific : ICDs and PM, Catheter Ablation</li> <li>- Medtronic : Implantable Loop Recorders , PM and ICDs, Cryoablation</li> <li>- Bayer : NOAC</li> <li>- Boehringer-Ingelheim : NOAC</li> <li>- Daiichi Sankyo : NOAC</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Puererfellner Helmut	<b>2019</b> - Bristol Myers Squibb : NOAC
Puodziukynas Aras	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Pfizer : Apixaban</li> <li>- Boehringer-Ingelheim : Dabigatran</li> <li>- Servier : Edoxaban</li> <li>- Bayer : Rivaroxaban</li> <li>- Mylan : Verapamil</li> </ul>
Raatikainen Pekka	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Abbott : Cardia rhythm management</li> <li>- Biosense Webster : Cardiac rhythm management</li> <li>- Pfizer/BMS : Oral anticoagulation</li> </ul> Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself <ul style="list-style-type: none"> <li>- Biosense Webster : Ventricular tachyarrhythmia ablation (unrestricted grant for international multicenter trial))</li> </ul>
Rakisheva Amina	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Bayer : speaker fees</li> <li>- Novartis : speaker fees</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Rakishva Amina	<b>2019</b> Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Servier : participated in the Servier advanced cardiovascular school during ESC congress 2019 in Paris and Heart Failure Congress 2019 in Athens
Richter Dimitrios	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Astra Zeneca : diabetes - Boehringer-Ingelheim : diabetes - Unipharm : hypertension-thrombosis - Amgen : lipids - Servier : LIPIDS - Sanofi Aventis : Lipids - Lilly : Lipids - Unilever : lipids - Merck Sharp & Dohme : lipids - Vianex : lipids - Mylan : lipids - ELPEN : LIPIDS-THROMBOSIS - Bayer Healthcare : Thrombosis  Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Amgen : LIPIDS - Bayer : THROMBOSIS

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Roffi Marco	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Stents</li> <li>- Medtronic : Stents</li> <li>- Biotronik : stents</li> <li>- GE Healthcare : stents</li> </ul>
Rubboli Andrea	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Antithrombotics in atrial fibrillation and PCI</li> </ul>
Sammut Mark Adrian	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Devices</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Biotronik : Devices and ablation</li> </ul>
Scherr Daniel	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Speaker fee</li> <li>- Daiichi Sankyo : Speaker fee</li> <li>- Medtronic : Speaker fee</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Scherr Daniel	<b>2019</b> <ul style="list-style-type: none"> <li>- Pfizer : Speaker fee</li> <li>- Biotronik : Speaker fee</li> <li>- Bayer Healthcare : Speaker fee</li> <li>- Zoll Medical : Speaker fee</li> </ul>
Schnabel Renate B	<b>2019</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For members of your household</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb/Pfizer : Atrial fibrillation, anticoagulation</li> </ul>
Shalghanov Tchavdar	<b>2019</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Actavis : ECG training course</li> <li>- Tchaikapharma : flecainide for arrhythmia treatment</li> <li>- Bayer : uninterrupted oral anticoagulation in atrial fibrillation ablation</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : arrhythmias - Europace 2019</li> </ul>
Shlyakhto Evgeny	<b>2019</b> <p>Nothing to be declared</p>
Siliste Calin	<b>2019</b> <p>Nothing to be declared</p>
Simpson Iain A	<b>2019</b> <p>Nothing to be declared</p>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Sinner Moritz	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Biotronik : Travel Support</li> <li>- Bayer Vital : Travel Support</li> </ul>
Sisakian Hamayak	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : arterial hypertension, CAD, HF</li> <li>- Servier : Heart afilure, Arterial Hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Servier : CAD, HF</li> </ul>
Smajic Elnur	<p><b>2019</b></p> <p>Nothing to be declared</p>
Sousa Uva Miguel	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Cardiothoracic Surgery</li> </ul>
Steffel Jan	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulation</li> <li>- Pfizer : Anticoagulation</li> </ul>



## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Steffel Jan	<p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Anticoagulation</li> <li>- Bristol Myers Squibb : Anticoagulation</li> <li>- Merck Sharp &amp; Dohme : Anticoagulation</li> <li>- Boehringer-Ingelheim : Anticoagulation, Diabetes</li> <li>- Astra Zeneca : Antidiabetics</li> <li>- Amgen : Atherosclerosis, dyslipidemia</li> <li>- Boston Scientific : Cardiac Devices</li> <li>- Medtronic : Cardiac devices, ablation</li> <li>- Abbott : Cardiac devices, electrophysiology</li> <li>- Biotronik : Cardiac devices, electrophysiology</li> <li>- Medscape : Education</li> <li>- Biosense Webster : Electrophysiology</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Travel support ESC 2019</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Ownership of CorXL (est. 2011) - <a href="http://www.corxl.com">www.corxl.com</a></li> </ul>
Sticherling Christian	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Ablation</li> <li>- Microport : Defibrillators, Pacemaker</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Sticherling Christian	<p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Boston Scientific : Defibrillators, Pacemaker, Ablation</li> <li>- Medtronic : Defibrillators, Pacemaker, Ablation</li> <li>- Biotronik : Defibrillators, Pacemaker, Ablation</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Biotronik : CRM</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Ablation, Loop recorder</li> <li>- Biosense Webster : Atrial fibrillation</li> </ul>
Suwalski Piotr	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : cardiovascular surgery</li> <li>- St Jude Medical : cardiovascular surgery</li> <li>- Atricure : cardiovascular surgery</li> </ul>
Svetlosak Martin	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Consultant (technical support of implanted devices and remote monitoring)</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Speaker Fees (Cardiac Arrhythmias: Management of asymptomatic premature supraventricular and ventricular contractions - Lecture)</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Svetlosak Martin	<p><b>2019</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Travel Grant for EHRA 2019 Congress</li> <li>- Biotronik : Travel grant for ESC 2019 Congress</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- ESC, EHRA, Slovak Society of Cardiology, Slovak Heart Rhythm Association, Slovak Medical Chamber</li> </ul>
Sychov Oleg	<p><b>2019</b></p> <p>Nothing to be declared</p>
Touyz Rhian	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Hypertension</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- I am Editor in Chief of Clinical Science I am Deputy Editor of Hypertension</li> </ul>
Vassilikos Vasilios P	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : NATIONAL COORDINATOR GLORIA AF STUDY</li> </ul>

## 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Vassilikos Vassilios P	<p><b>2019</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : EXPERTS MEETING</li> <li>- Medtronic : TRAINING FOR MICRA PACEMAKER</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- St Jude Medical : ELECTROPHYSIOLOGY</li> <li>- Vifor International : HEART FAILURE</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. For yourself</p> <ul style="list-style-type: none"> <li>- MEMBER OF THE NATIONAL COMMITTEE FOR CARDIOLOGY SPECIALTY IN GREECE</li> </ul>
Zakirov Nodir U	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- OlainFarm : Aethacizinium</li> <li>- Takeda Pharmaceuticals : Edarby, Warfarin</li> <li>- Promed Cs : propafenone</li> <li>- Bayer AG : Xarelto</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Aboyans Victor	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Bayer : Antithrombotic therapy</li> <li>- BMS/Pfizer Alliance : Antithrombotic therapy</li> <li>- NovoNordisk : Diabetes</li> <li>- Novartis : Heart Failure</li> <li>- Amgen : Lipid lowering therapy</li> <li>- Sanofi Aventis : PAD</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : PAD</li> </ul>
	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Antithrombotic therapy</li> <li>- BMS/Pfizer Alliance : Antithrombotic therapy</li> <li>- NovoNordisk : Diabetes</li> <li>- Novartis : Heart Failure</li> <li>- Amgen : Lipid lowering therapy</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapy</li> </ul>

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Baigent Colin	<b>2018</b> Financial Declaration  Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. - Boehringer-Ingelheim : Empagliflozin - Novartis : Sacubitril - Pfizer : Sirolimus
	<b>2019</b> Financial Declaration  Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Boehringer-Ingelheim : Empagliflozin
Collet Jean-Philippe	<b>2018</b> Financial Declaration  Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Bristol Myers Squibb : Apixaban - Astra Zeneca : TICAGRELOR  Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. - Bristol Myers Squibb : apixaban - Medtronic : COREVALVE
	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Astra Zeneca : Post-PCI antiplatelet traitement

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Post-TAVR antithrombotic treatment</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Post-TAVR antithrombotic treatment</li> <li>- Bristol Myers Squibb : Post-TAVR antithrombotic treatment</li> </ul>
Delgado Victoria	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : Mitraclip</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- GE Healthcare : Echocardiography</li> <li>- Edwards Lifesciences : Transcatheter valve interventions</li> </ul> <hr/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- GE Healthcare : 3-dimensional imaging workshop (2000 euro)</li> <li>- Medtronic : aortic stenosis (payment speaker fee 900 euro)</li> <li>- Bayer : diabetes - steering committee (750 euro)</li> <li>- Abbott Vascular : Mitraclip (payment speaker fee 1200 euro)</li> <li>- Edwards Lifesciences : tricuspid valve (payment speaker fee 1200 euro)</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Aortic valve stenosis</li> </ul>

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Delgado Victoria	<p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Bayer : Heart failure</li> <li>- Bioventrix : heart failure</li> <li>- Abbott Vascular : Mitraclip</li> <li>- Edwards Lifesciences : Tricuspid valve</li> </ul>
Fitzsimons Donna	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Medscape : Heart failure</li> </ul> <hr/> <p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. For yourself</p> <ul style="list-style-type: none"> <li>- Member of Scientific Advisory Board of Northern Ireland Chest Heart &amp; Stroke (Non-Paid)</li> </ul>
Gale Christopher Peter	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : ACS</li> <li>- Novartis : coronary artery disease</li> <li>- Bayer : coronary artery disease, AF</li> <li>- Vifor International : heart failure</li> <li>- Menarini : ischaemic heart disease</li> </ul>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Gale Christopher Peter	<b>2018</b> Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. - Bristol Myers Squibb : Apixiban, AF
	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Astra Zeneca : ACS - Daiichi Sankyo : AF - Novartis : coronary artery disease - Bayer : coronary artery disease, AF - Vifor International : heart failure - Menarini : ischaemic heart disease  Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - BMS : AF - Abbott : Diabetes - National Institute for Health Research : MI - British Heart Foundation : MI, AF - Horizon 2020 : post MI sudden cardiac death  Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Daiichi Sankyo : AF - Bayer Healthcare : AF, CAD - National Institute for Health and Clinical Excellence : Indicator Advisory Committee

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Gale Christopher Peter	<b>2019</b> Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Bristol Myers Squibb : Apixiban, AF
Grobbee Diederick E	<b>2018</b> Financial Declaration  Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Amgen : advisory board - Esperion : Steering ctt  Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. - Esperion : clinical trial lipids  Other Positions of Influence  Employment in healthcare industry (including part time) during the year for which you are declaring. - chief scientific officer Julius Clinical Research Ltd (part-time)
	<b>2019</b> Financial Declaration  Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Amgen : advisory board - Esperion : Steering ctt  Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Esperion : clinical trial lipids

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Grobbee Diederick E	<p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. For yourself</p> <ul style="list-style-type: none"> <li>- Chief Scientific Officer Julius Clinical Academic Contract Research Organization Staff Member, University Medical Center Utrecht</li> </ul>
Halvorsen Sigrun	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Antithrombotic treatment</li> <li>- Astra Zeneca : Anti-thrombotic treatment</li> <li>- Boehringer-Ingelheim : Anti-thrombotic treatment</li> <li>- Pfizer : Anti-thrombotic treatment</li> <li>- Bayer AS : Anti-thrombotic treatment</li> <li>- Sanofi Aventis : Cholesterol lowering treatment</li> </ul> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart failure</li> </ul>
	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulation</li> <li>- Pfizer : Anticoagulation</li> <li>- Bristol Myers Squibb : Anticoagulation</li> </ul>

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Halvorsen Sigrun	<b>2019</b> <ul style="list-style-type: none"> <li>- Bayer AS : Anticoagulation</li> <li>- Merck Sharp &amp; Dohme : Glucose lowering drugs</li> <li>- Sanofi Aventis : Lipid lowering treatment</li> </ul>
Hindricks Gerhard	<b>2018</b> <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Abbott : Pacemaker, Ablation</li> <li>- Biosense Webster : Pacemaker, Ablation</li> <li>- Biotronik : Pacemaker, catheter</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Electrophysiology, arrhythmias</li> <li>- Abbott : Electrophysiology, arrhythmias</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group.</li> </ul> <hr/> <b>2019</b> <p>Nothing to be declared</p>

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Iung Bernard	<b>2018</b> Financial Declaration  Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Boehringer Ingelheim : Anticoagulants - Edwards Lifesciences : Heart valve prostheses
	<b>2019</b> Financial Declaration  Travel and meeting support from healthcare industry, independent of the above activities. For yourself - Abbott : Cardiovascular devices
Juni Peter	<b>2018</b> Financial Declaration  Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. - Astra Zeneca : Anti-platelet Therapy - Biotronik : Drug-eluting stents - Biosensors International Group : Drug-eluting stents - The Medicines Company : Thrombin inhibitors  Other Positions of Influence  Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Peter Jüni serves as unpaid member of the steering group of trials funded by St. Jude Medical.

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Juni Peter	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Fresenius Nutrition : ECCO2R in COPD</li> <li>- Ava : Fertility App</li> <li>- Amgen Inc : PCSK9 inhibitors in Patients at Cardiovascular Risk</li> </ul> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. For yourself</p> <ul style="list-style-type: none"> <li>- Director, Applied Health Research Centre, St. Michael's Hospital</li> </ul> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> <li>- Peter Jüni serves as unpaid member of the steering group of trials funded by Abbott Vascular, Astra Zeneca, Biotronik, Biosensors, St. Jude Medical, Terumo and The Medicines Company, has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and honoraria to the institution for participation in advisory boards and/or consulting from Amgen, Ava and Fresenius, but has not received personal payments by any pharmaceutical company or device manufacturer.</li> </ul>
Katus Hugo	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulants</li> <li>- Bayer Vital : Anticoagulants</li> <li>- Astrazeneca : Antiplatelet</li> <li>- Roche Diagnostics : Biomar</li> </ul>

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Katus Hugo	<p><b>2018</b></p> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Roche Diagnosticsarker : Biomarker</li> <li>- Daiichi Sankyo : Xarelto</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- President of the German Society of Cardiology</li> </ul>
	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulants</li> <li>- Bayer Vital : Anticoagulants</li> <li>- Astrazeneca : Antiplatelet</li> <li>- Novartis : Heart Failure Therapies</li> <li>- Boston Scientific : PCI</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulations</li> <li>- Roche Diagnosticsarker : Biomarker</li> </ul>
Landmesser Ulf	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Abbott : Advisory Board fees</li> </ul>

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p><b>2018</b></p> <ul style="list-style-type: none"> <li>- Medicines Company : Advisory Board fees</li> <li>- Amgen : Speaker fees</li> <li>- Sanofi Aventis : Speaker fees</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Bayer AG : Research Grant</li> </ul>
	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Advisory Board fees</li> <li>- Medicines Company : Advisory Board fees</li> <li>- Bayer : Speaker fee</li> <li>- Amgen : Speaker fees</li> <li>- Sanofi Aventis : Speaker fees</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Research Grant</li> </ul>
Leclercq Christophe	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Abbott : devices</li> <li>- Boston Scientific : devices</li> <li>- Medtronic : devices</li> <li>- Biotronik : devices</li> </ul>



## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Leclercq Christophe	<b>2018</b> Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Biotronik : devices
	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Abbott : devices - Boston Scientific : devices - Medtronic : devices - Biotronik : devices - Microport : devices - Zoll Medical : WCD
Lettino Maddalena	<b>2018</b> Financial Declaration  Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Daiichi Sankyo : Anticoagulants - Pfizer : Anticoagulants - Bayer Healthcare : Antithrombotic agents, anticoagulants - Sanofi Aventis : Antithrombotic agents, anticoagulants, lipid lowering drugs - Astra Zeneca : Antithrombotic agents, statins

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Lettino Maddalena	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : anticoagulants</li> <li>- Daiichi Sankyo : anticoagulants</li> <li>- Pfizer : anticoagulants</li> <li>- Bristol Myers Squibb : anticoagulants</li> <li>- Amgen : lipid-lowering drugs</li> <li>- Sanofi Aventis : lipid-lowering drugs</li> </ul>
Lewis Basil S	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Pfizer : Antithrombotics</li> <li>- Astra Zeneca : Diabetes</li> <li>- Merck Sharp &amp; Dohme : Heart failure</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Astrazeneca : Antithrombotics</li> <li>- Astra Zeneca : Diabetes</li> <li>- Pfizer : Diabetes</li> <li>- Merck Sharp &amp; Dohme : Heart failure</li> </ul>

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Lewis Basil S	<b>2018</b> <ul style="list-style-type: none"> <li>- Kowa : Lipidology</li> <li>- Resverlogix : Lipidology. secondary prevention</li> </ul>
	<b>2019</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novo-Nordisk : Diabetes</li> <li>- Merck Sharp &amp; Dohme : Heart failure</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Diabetes</li> <li>- Merck Sharp &amp; Dohme : Heart failure</li> <li>- Kowa : Lipidology</li> <li>- Resverlogix : Lipidology. secondary prevention</li> </ul>
Merkely Bela	<b>2018</b> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Medtronic : CRT course</li> <li>- Abbott : CRT/ICD</li> <li>- Astra Zeneca : HF</li> <li>- Biotronik : ICD/CRT</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Merkely Bela	<p><b>2018</b></p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Medtronic : cardiac rhythm management</li> <li>- Boston Scientific : CRT</li> </ul>
	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : CRT course</li> <li>- Abbott : CRT/ICD</li> <li>- Astra Zeneca : HF</li> <li>- Biotronik : ICD/CRT</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : cardiac rhythm management</li> <li>- Boston Scientific : CRT</li> </ul>
Mueller Christian Eugen	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Antidiabetics</li> <li>- Indorsia : Antiplatelet therapy</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Sanofi Aventis : Lipid lowering</li> <li>- Amgen : Lipid-lowering</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Mueller Christian Eugen	<p><b>2018</b></p> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Beckman Coulter : Diagnostics</li> <li>- OrthoClinical Diagnostics : Diagnostics</li> <li>- Singulex : Diagnostics</li> <li>- Abbott Laboratories : Diagnostics</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Siemens : Diagnostics</li> <li>- Sphingotec : Diagnostics</li> <li>- quidel : Diagnostics</li> </ul>
	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulants</li> <li>- Daiichi Sankyo : Anticoagulants</li> <li>- Boehringer-Ingelheim : Antidiabetics</li> <li>- Astra Zeneca : Anti-Diabetics</li> <li>- Idorsia : Antiplatelet therapy</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Acon : Diagnostics</li> <li>- Novartis : Heart Failure</li> <li>- Sanofi Aventis : Lipid lowering</li> <li>- Amgen : Lipid-lowering</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Mueller Christian Eugen	<p><b>2019</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Diagnostics</li> <li>- OrthoClinical Diagnostics : Diagnostics</li> <li>- Abbott Laboratories : Diagnostics</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Siemens : Diagnostics</li> <li>- Sphingotec : Diagnostics</li> <li>- quidel : Diagnostics</li> </ul>
Petersen Steffen Erhard	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</li> <li>- Servier : Heart failure</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> <li>- Healthcare - IMAGING - I have option for shares for Circle Cardiovascular Imaging Inc.</li> </ul> <hr/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</li> </ul>

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself</p> <ul style="list-style-type: none"> <li>- Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</li> </ul> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. For yourself</p> <ul style="list-style-type: none"> <li>- Member of the advocacy committee for the Society of Cardiovascular Magnetic Resonance (SCMR).</li> </ul>
Petronio Anna Sonia	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Percutaneous Aortic and Mitral treatment</li> <li>- Medtronic : Percutaneous Aortic and mitral treatment</li> <li>- Abbott : Percutaneous Mitral treatment</li> </ul> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : TAVI research</li> </ul> <hr/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Structural heart disease</li> <li>- Abbott : structural valve disease</li> </ul>

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Petronio Anna Sonia	<p><b>2019</b></p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : structural heart disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : coronary disease, valve disease</li> <li>- GaDA : valve disease</li> </ul>
Priori Silvia Giuliana	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Cardiac device</li> </ul> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Audentes Rx : Gene therapy</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Takeda Pharmaceuticals : antiarrhythmic drugs</li> </ul> <hr/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Cardiac Device</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Takeda Pharmamaceuticals : Anti-arrhythmic drugs</li> </ul>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Richter Dimitrios	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : aortic stenosis</li> <li>- Menarini : CAD- hypertension</li> <li>- Unipharma : hypertension-thrombosis</li> <li>- Abbott : lipids</li> <li>- Amgen : lipids</li> <li>- Servier : LIPIDS</li> <li>- Sanofi Aventis : Lipids</li> <li>- Lilly : Lipids</li> <li>- Unilever : lipids</li> <li>- Merck Sharp &amp; Dohme : lipids</li> <li>- Vianex : lipids</li> <li>- RAFARM : LIPIDS</li> <li>- ELPEN : LIPIDS-THROMBOSIS</li> <li>- Bayer Healthcare : Thrombosis</li> <li>- Leo Pharma : THROMBOSIS</li> <li>- NovaGEM CYPRUS : THROMBOSIS</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Richter Dimitrios	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : diabetes</li> <li>- Boehringer-Ingelheim : diabetes</li> <li>- Unipharma : hypertension-thrombosis</li> <li>- Amgen : lipids</li> <li>- Servier : LIPIDS</li> <li>- Sanofi Aventis : Lipids</li> <li>- Lilly : Lipids</li> <li>- Unilever : lipids</li> <li>- Merck Sharp &amp; Dohme : lipids</li> <li>- Vianex : lipids</li> <li>- Mylan : lipids</li> <li>- ELPEN : LIPIDS-THROMBOSIS</li> <li>- Bayer Healthcare : Thrombosis</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : LIPIDS</li> <li>- Bayer : THROMBOSIS</li> </ul>
Roffi Marco	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Stents</li> </ul>

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Roffi Marco	<b>2018</b> <ul style="list-style-type: none"> <li>- Medtronic : Stents</li> <li>- Biotronik : stents</li> <li>- Terumo Inc : stents</li> <li>- Abbott Vascular : stents</li> </ul>
	<b>2019</b> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Stents</li> <li>- Medtronic : Stents</li> <li>- Biotronik : stents</li> <li>- GE Healthcare : stents</li> </ul>
Shlyakhto Evgeny	<b>2018</b> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Krka Pharma : Arterial Hypertension</li> <li>- Novartis : Arterial Hypertension, Heart Failure</li> <li>- Merck Sharp &amp; Dohme : Atherosclerosis</li> <li>- Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation</li> <li>- Pfizer : General Cardiology</li> </ul>
	<b>2019</b> <p>Nothing to be declared</p>
Simpson Iain A	<b>2018</b> <p>Nothing to be declared</p>

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Simpson Iain A	<b>2019</b> Nothing to be declared
Sousa Uva Miguel	<b>2018</b> Financial Declaration  Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Abott : Surgical Valves
	<b>2019</b> Financial Declaration  Travel and meeting support from healthcare industry, independent of the above activities. For yourself - Medtronic : Cardiothoracic Surgery
Touyz Rhian	<b>2018</b> Financial Declaration  Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Novartis : antihypertensive drugs - Alnylam : antihypertensive drugs  Research funding (personal). - British Heart Foundation : Hypertension research - Medical Research Council, UK : Hypertension research  Other Positions of Influence  Membership or affiliation in political or advocacy groups working in the field of cardiology. - American Heart Association International Society of Hypertension British Irish Hypertension Society

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Touyz Rhian	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Hypertension</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> <li>- I am Editor in Chief of Clinical Science I am Deputy Editor of Hypertension</li> </ul>
Windecker Stephan	<p><b>2018</b></p> <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- CSL Behring : Invasive Cardiology</li> <li>- Polares Medical : Invasive Cardiology</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Abbott : General Cardiology</li> <li>- Boston Scientific : General Cardiology</li> <li>- Edwards Lifesciences : General Cardiology</li> <li>- Medtronic : General Cardiology</li> <li>- Biotronik : General Cardiology</li> <li>- Amgen Inc : General Cardiology</li> <li>- Bristol Myers Squibb : General Cardiology</li> <li>- Bayer AG : General Cardiology</li> <li>- Sinomed : General Cardiology</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Windecker Stephan	<p><b>2018</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entrepreneur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR</li> </ul>
	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Anticoagulation</li> <li>- Amgen : Dyslipidemia</li> <li>- Johnson &amp; Johnson : Electrophysiology and General Cardiology</li> <li>- Daiichi Sankyo : General Cardiology</li> <li>- Terumo Inc : General Cardiology</li> <li>- Sanofi Aventis : General Cardiology</li> <li>- Bayer AG : General Cardiology</li> <li>- CSL Behring : General Cardiology</li> <li>- Cardinal health : General Cardiology</li> <li>- Guerbet AG : General Cardiology</li> <li>- Abbott : Invasive Cardiology</li> <li>- Boston Scientific : Invasive Cardiology</li> <li>- Edwards Lifesciences : Invasive Cardiology</li> <li>- Medtronic : Invasive Cardiology and Electrophysiology</li> <li>- Biotronik : Invasive Cardiology and Electrophysiology</li> </ul>

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Windecker Stephan	<p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <p>- Deputy Editor JACC CV Intervention , Section Editor Uptodate, Course Director PCR</p>